Format
Sort by
Items per page

Send to

Choose Destination

Best matches for myeloproliferative neoplasms:

Myeloproliferative Neoplasms. Spivak JL et al. N Engl J Med. (2017)

Myeloproliferative neoplasms: from origins to outcomes. Nangalia J et al. Blood. (2017)

Myeloproliferative neoplasms: from origins to outcomes. Nangalia J et al. Hematology Am Soc Hematol Educ Program. (2017)

Search results

Items: 1 to 20 of 46742

1.

JMML genomics and decisions.

Niemeyer CM.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):307-312. doi: 10.1182/asheducation-2018.1.307. Review.

PMID:
30504325
2.

JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Ciboddo M, Mullally A.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):110-117. doi: 10.1182/asheducation-2018.1.110. Review.

PMID:
30504299
3.

Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Ferreira Cristina S, Polo B, Lacerda JF.

Semin Hematol. 2018 Oct;55(4):215-222. doi: 10.1053/j.seminhematol.2018.04.005. Epub 2018 Apr 17. Review.

PMID:
30502850
4.

The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.

Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Am J Hematol. 2018 Dec 5. doi: 10.1002/ajh.25349. [Epub ahead of print]

PMID:
30516848
5.

Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Asada S, Kitamura T.

Int J Hematol. 2018 Dec 5. doi: 10.1007/s12185-018-2563-7. [Epub ahead of print] Review.

PMID:
30515738
6.

JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing.

Mahe E, Pedersen KM, Çolak Y, Bojesen SE, Lynch T, Sinclair G, Khan F, Shabani-Rad MT.

J Clin Pathol. 2018 Dec 4. pii: jclinpath-2018-205527. doi: 10.1136/jclinpath-2018-205527. [Epub ahead of print]

7.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Brattås MK, Lilleeng K, Hovland R, Lægreid IJ, Vorland M, Leh F, Bruserud Ø, Gjertsen BT, Reikvam H.

Biomark Res. 2018 Nov 21;6:33. doi: 10.1186/s40364-018-0147-6. eCollection 2018.

8.

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM.

Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9. No abstract available.

9.

Knockout of both miR-15/16 loci induces acute myeloid leukemia.

Lovat F, Fassan M, Sacchi D, Ranganathan P, Palamarchuk A, Bill M, Karunasiri M, Gasparini P, Nigita G, Distefano R, Veneziano D, Dorrance AM, Garzon R, Croce CM.

Proc Natl Acad Sci U S A. 2018 Nov 26. pii: 201814980. doi: 10.1073/pnas.1814980115. [Epub ahead of print]

PMID:
30478046
10.

Targeted therapy of polycytemia vera patients.

Shikhbabaeva DI, Shuvaev VA, Martynkevich IS, Zyuzgin IS, Abdulkadyrov KM.

Vopr Onkol. 2016;62(4):386-93. Russian.

PMID:
30474944
11.

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S.

Leukemia. 2018 Nov 23. doi: 10.1038/s41375-018-0295-6. [Epub ahead of print]

PMID:
30470838
12.

Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.

Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S.

Acta Haematol. 2018 Nov 21;141(1):23-27. doi: 10.1159/000494427. [Epub ahead of print]

PMID:
30463063
13.

Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.

Li Y, Zhang XY, Han J, Wang L.

Cancer Biomark. 2018 Nov 4. doi: 10.3233/CBM-171145. [Epub ahead of print]

PMID:
30452397
14.

Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.

Brabrand M, Hansen KN, Laursen CB, Larsen TS, Vestergaard H, Abildgaard N.

Eur J Haematol. 2018 Nov 19. doi: 10.1111/ejh.13197. [Epub ahead of print]

PMID:
30450659
15.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2018 Nov 15. pii: haematol.2018.204602. doi: 10.3324/haematol.2018.204602. [Epub ahead of print]

16.

Targeting the CALR interactome in myeloproliferative neoplasms.

Pronier E, Cifani P, Merlinsky TR, Berman KB, Somasundara AVH, Rampal RK, LaCava J, Wei KE, Pastore F, Maag JL, Park J, Koche R, Kentsis A, Levine RL.

JCI Insight. 2018 Nov 15;3(22). pii: 122703. doi: 10.1172/jci.insight.122703. [Epub ahead of print]

17.

Mutations and prognosis in myeloproliferative neoplasms.

Tefferi A, Pardanani A.

Leuk Lymphoma. 2018 Nov 14:1-2. doi: 10.1080/10428194.2018.1537490. [Epub ahead of print] No abstract available.

PMID:
30424706
18.

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia.

Musumeci F, Greco C, Grossi G, Molinari A, Schenone S.

Cancers (Basel). 2018 Nov 9;10(11). pii: E430. doi: 10.3390/cancers10110430. Review.

19.

JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

Celik H, Koh WK, Kramer AC, Ostrander EL, Mallaney C, Fisher DAC, Xiang J, Wilson WC, Martens A, Kothari A, Fishberger G, Tycksen E, Karpova D, Duncavage EJ, Lee Y, Oh ST, Challen GA.

Cancer Cell. 2018 Nov 12;34(5):741-756.e8. doi: 10.1016/j.ccell.2018.10.008.

PMID:
30423295
20.

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.

Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, Fiedler M, Novak U, Amstutz U, Pabst T.

Blood Cancer J. 2018 Nov 12;8(11):113. doi: 10.1038/s41408-018-0148-6. Review.

Supplemental Content

Loading ...
Support Center